Alder BioPharmaceuticals Inc
Competition Dynamics for Ajovy—Teva’s Migraine Drug
Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.
What Will Help Eli Lilly Build a Stronger Migraine Portfolio?
In September, Eli Lilly presented the results of its phase-3 Spartan trial, in which Lasmiditan demonstrated significant progress in the treatment of migraines.